Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Dec 6, 2012
FAQ: Why Doesn't the 'Percentage Undervalued/Overvalued' Match Up to the Actual Discount/Premium to Valuentum's Fair Value Estimate of the Company?
We answer a question about a potentially confusing part of our reports. Dec 5, 2012
FAQ: How Is Your Best Ideas Portfolio Doing This Year?
We answer a question that has come up a lot recently. Oct 31, 2012
5 Highly Ranked Dividend Growth Stocks
Let's take a look at 5 highly ranked dividend growth stocks. Oct 27, 2012
AstraZeneca Is Not Immune to Patent Cliff
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance. Jul 31, 2012
Pfizer Reports Decent Second Quarter Results; Plans to Spin Off Animal Health Business
Pfizer posted decent second-quarter results that showed strong cost containment in the face of declining sales of its blockbuster drug Lipitor. The company also announced plans to spin off its animal health business to focus on its core pharma business. We maintain our view that Pfizer is significantly underpriced. Jul 19, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market. Jul 2, 2012
Bristol-Myers Squibb and AstraZeneca Purchase Amylin
The two pharmaceutical companies will collaborate to commercialize the diabetes portfolio of Amylin. We think the deal is value neutral. Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry. Nov 2, 2011
Pfizer Reports Decent Third-Quarter Results; Loss of Exclusivity on Blockbuster Drug Lipitor Concerning
All things considered, we're less than thrilled with Pfizer. The firm will be losing exclusivity on its $10-billion-per-year blockbuster drug Lipitor at the end of November, and its earnings-per-share expansion is largely driven by buybacks. Though its valuation is compelling, there are better opportunities out there. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Let's take a look at Abbott's new standalone business, AbbVie.